cagrilintide and semaglutide 2.4mg Efficacy safety of co-administered once-weekly 2·4 mg with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Cagrilintide + Semaglutide — Factor

(3)Fmoc-Gly-Leu-Val-WangResin (3) Preparation of Fmoc-Gly-Leu-Val-WangResin (2)Fmoc-Leu-Val-WangResin(20DMF)5203DMF3DMF2Fmoc-Gly-OH0.7gDIEA0.4mlTBTU0.56gHOBT0.2gDMF10ml1.53DMF3DMF2Fmoc-Gly-Leu-Val-WangResin In the Fmoc-Leu-Val-WangResin of step (2), add decapping reagent (DMF solution of 20% piperidine), react at room temperature for 5 minutes, drain, add decapping reagent at room temperature and react for 20 minutes, wash with isopropanol 3 times, washed 3 times with DMF, washed 2 times with re-distilled DMF, drained, added Fmoc-Gly-OH0.7g, DIEA0.4ml, TBTU0.56g, HOBT0.2g, DMF10ml, reacted at room temperature for 1.5 hours, pumped with a vacuum pump Dry, wash 3 times with isopropanol, wash 3 times with DMF, wash 2 times with DMF that has been distilled, and drain to obtain Fmoc-Gly-Leu-Val-WangResin

Ethics declarations Conflict of interest Mette JF Nielsen, Helene H Hansen Duus, Katrine Kirkeby, Britt W Lauenborg, Benjamin Low and Louise Witten are employees and stockholders of Novo Nordisk A/S

10.1039/d1md00041a RSC Med

A rat retinal ischemia study was conducted throughout 4 weeks, including fundoscopy, behavior presentation, tonometry, and histology assessment